Home/Browse by collection/Clinical/Translational Cancer Immunotherapy

Clinical/Translational Cancer Immunotherapy

Section Edited by Douglas G. McNeel, MD, PhD; Claudia Palena, PhD; and Jeffrey S. Weber, MD, PhD First-in-man clinical trials (prospective clinical data only); phase II/III clinical studies; immune monitoring investigations;.

Showing results 31 - 40 of 100

Sorted by most recent

Blinatumomab as postremission therapy replaces consolidation and substantial parts of maintenance chemotherapy and results in stable MRD negativity in children with newly diagnosed B-lineage ALL
Ekaterina Mikhailova, Alexander Popov, Julia Roumiantseva, Oleg Budanov, Svetlana Lagoyko, Liudmila Zharikova, Natalia Miakova, Dmitry Litvinov, Lili Khachatryan, Alexey Pshonkin, Natalia Ponomareva, Elmira Boichenko, Svetlana Varfolomeeva, Julia Dinikina, Galina NovichkovaSee the full list of authors

6 June 2024